Author:
Höfner K.,Ulrich S.,Berges R.
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Cho SH, Lee SK (2003) The Experience with combination of finasteride and tamsulosin on benign prostatic hyperplasia. Korean J Urol 44:1110–1115
2. Chu N, Xu H, Wang G et al (2015) Pharmacokinetic interaction of finasteride with tamsulosin hydrochloride: an open-label, randomized, 3‑period crossover study in healthy Chinese male volunteers. Clin Ther 37:462–472
3. Debruyne FM, Jardin A, Colloi D et al (1998) Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 34:169–175
4. Gravas S, Bach T, Bachmann A et al (2016) EAU Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). In: European Association of Urology. http://uroweb.org/wp-content/uploads/EAU-Guidelines-Management-of-non-neurogenic-male-LUTS-2016.pdf . Zugegriffen: 11.Okt 2016
5. Hazlehurst JM, Oprescu AI, Nikolaou N et al (2016) Dual-5α-reductase inhibition promotes hepatic lipid accumulation in man. J Clin Endocrinol Metab 101:103–113
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献